Cyclin Dependent Kinases as Attractive Targets to Prevent Transcription from Viral Genomes

Authors: Kashanchi, Fatah; Kehn-Hall, Kylene

Source: Current Pharmaceutical Design, Volume 15, Number 21, July 2009 , pp. 2520-2532(13)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

Price: $63.10 plus tax (Refund Policy)

Abstract:

Most viral treatments target the virus itself, providing very specific effects and limiting side-effects on uninfected cells. However, this strategy of drug design often results in resistant viruses, especially among RNA viruses. Therefore, the focus has turned to drugs that target cellular proteins that are essential for viral replication, but not for cellular viability. Pharmacological CDK inhibitors are a prime example of this type of approach. Reviewed within are the various functions of CDKs, their role in the life cycle of selected Retroviruses and Herpesviruses, and the pharmacological CDK inhibitors that have been focused on in terms of viral inhibition.

Keywords: CDK; transcription; cyclin; HIV-1; HTLV-1; inhibitors; roscovitine; viral; treatment; herpesviruses

Document Type: Research article

DOI: http://dx.doi.org/10.2174/138161209788682280

Affiliations: 1: George Washington University, Department of Microbiology, Immunology, and Tropical Medicine, 2300 I Street, NW, Washington, DC 20037, USA.

Publication date: 2009-07-01

More about this publication?

Current Pharmaceutical Design publishes timely in-depth reviews covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area. A Guest Editor who is an acknowledged authority in a therapeutic field has solicits for each issue comprehensive and timely reviews from leading researchers in the pharmaceutical industry and academia.

Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design, including: medicinal chemistry, pharmacology, drug targets and disease mechanism.